Earlier this month, I sat down for a Pulse Check with Dr. Patrick O’Shaughnessy, president and CEO of Catholic Health: a six ...
Shares of Danish rival Novo Nordisk slipped after it sought to snatch Pfizer target Metsera from the American drug giant's arms. Novo launched an unsolicited bid valued at up to $9 billion for obesity ...
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Discover Eli Lilly’s Q3 2025 earnings highlights: record 54% revenue growth, new product approvals, raised guidance, and global expansion.
Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica ...
In an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management medication, now available for patients in India. With Cipla handling nationwide ...
Knownwell picked up $25 million in fresh funding, riding the wave of investment in obesity care. | LAS VEGAS—Over the last 18 ...
U.S. stocks wavered amid increased volatility on Friday but managed to resurge, as Wall Street was rattled by concerns on the health of regional banks and credit risks while the U.S. government ...
With 80% of FDA approvals now classified as specialty products, commercial teams must rethink how they bring medicines to market, said Matt Lehmann, executive vice president, Global Commercial ...
As pharma giant Eli Lilly builds out its direct-to-consumer care site, LillyDirect, the company has tapped virtual primary care company HealthTap to join its small lineup of independent care providers ...
President Trump has made lowering health care costs a key priority, even as Democrats warn that costs will skyrocket. By Erica L. Green Reporting from Washington On the first day of the government ...
Those without legal status aren't entitled to federally funded health insurance. As the nation careens towards a likely government shutdown, President Donald Trump and top Republicans, including Vice ...